ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.

individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal \< 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous

individualized, once daily, dose to reach mean fasting plasma glucose (FPG) \<= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous

1000 mg b.i.d, since the qualification phase, oral